LianMedical
LIANY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.74M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.74 Million |
|---|---|
| Enterprise Value | $-431,384,723.00 |
| Earnings per Share | $0.05 |
| Beta | 0.07 |
| Outstanding Shares | 107,781,000 |
Return
| Return on Equity | 54.03% |
|---|---|
| Return on Assets | 50.82% |
| Return on Invested Capital | 52.46% |
Valuation & Multiples
| P/E Ratio | 0.98 |
|---|---|
| PEG | -0.04 |
| Price to Sales | - |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.32 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.57
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-0.57
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%0% |
|---|---|
| Total Invested | $1,000 |
| Investors Holding | 10% |
About LianBio
163 employees
CEO: Adam Leo Stone
LianBio is a biopharmaceutical firm dedicated to advancing and marketing therapeutic agents across various critical health sectors, including cardiovascular disorders, oncology, ophthalmological conditions, and inflammatory ailments. Its...